FDA Approval of Orphan Drug Indications for Pediatric Patients, 2011-2023

被引：0
|
作者：
Kakkilaya, Apoorva [1 ]
Shahzad, Mahnum [2 ]
Bourgeois, Florence T. [3 ,4 ,5 ]
机构：
[1] Univ Texas Med Branch, John Sealy Sch Med, Galveston, TX USA
[2] Harvard Med Sch, Dept Populat Med, Harvard Pilgrim Hlth Care Inst, Boston, MA USA
[3] Harvard Med Sch, Harvard MIT Ctr Regulatory Sci, Boston, MA USA
[4] Harvard Med Sch, Dept Pediat, Boston, MA USA
[5] Boston Childrens Hosp, Computat Hlth Informat Program, Pediat Therapeut & Regulatory Sci Initiat, Boston, MA USA
来源：
JAMA PEDIATRICS | 2025年 / 179卷 / 02期
关键词：
D O I：
10.1001/jamapediatrics.2024.5280
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：203 / 205
页数：3
相关论文
共 46 条
  • [1] FDA ORPHAN EXPLOITATION? ARE PHARMA'S APPROACHES TO ORPHAN ONCOLOGY DRUG APPROVAL FUELLING A PUSH FOR REFORM BY THE FDA?
    Macaulay, R.
    Cieply, B.
    Wang, G. D.
    VALUE IN HEALTH, 2018, 21 : S260 - S261
  • [2] Synthetic Approaches to Piperazine-Containing Drugs Approved by FDA in the Period of 2011-2023
    Romanelli, Maria Novella
    Braconi, Laura
    Gabellini, Alessio
    Manetti, Dina
    Marotta, Giambattista
    Teodori, Elisabetta
    MOLECULES, 2024, 29 (01):
  • [3] Pediatric Orphan Drug Indications: 2010-2018
    Kimmel, Lauren
    Conti, Rena M.
    Volerman, Anna
    Chua, Kao-Ping
    PEDIATRICS, 2020, 145 (04)
  • [4] Clinical trial evidence supporting FDA approval of novel orphan drugs between 2017 and 2023
    Chen, Qi
    Xu, Yang
    Qu, Ruoxuan
    Luo, Xingxian
    Yang, Yue
    DRUG DISCOVERY TODAY, 2024, 29 (09)
  • [5] PEDIATRIC LIVER TRANSPLANT TRENDS AND OUTCOMES IN 2011-2023: A SINGLE-CENTER STUDY
    Alqahtani, Saleh
    Aldana, Alexandra
    Kumar, Kishwer
    Akhtar, Ali Syed Muhammad
    Albugami, Dalal
    Almuhaidib, Shadan
    Raptis, Dimitri
    Broering, Dieter
    Alghamdi, Saad
    Shagrani, Mohammad
    HEPATOLOGY, 2024, 80 : S1059 - S1060
  • [6] FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
    Michaeli, Thomas
    Juerges, Hendrik
    Michaeli, Daniel Tobias
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 381 : e073242
  • [7] Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development
    Donaldson, Joshua M.
    Seddiq, Marjilla
    Fusco, Michael J.
    Singla, Shyamli
    Pamuk, Gulsum E.
    Lee-Alonso, Rosa J.
    Mixter, Bronwyn D.
    Goldberg, Kirsten B.
    Amiri-Kordestani, Laleh
    De Claro, R. Angelo
    Drezner, Nicole
    Gormley, Nicole J.
    Kanapuru, Bindu
    Lemery, Steven J.
    Fashoyin-Aje, Lola A.
    Richardson, Nicholas C.
    Singh, Harpreet
    Suzman, Daniel L.
    Theoret, Marc R.
    Kluetz, Paul G.
    Pazdur, Richard
    CANCER DISCOVERY, 2023, 13 (12) : 2515 - 2524
  • [8] Pediatric Exposures Associated with Caffeine Energy Products Reported to United States Poison Centers, 2011-2023
    Thompson, Timothy R.
    Hays, Hannah L.
    Kistamgari, Sandhya
    Rine, Natalie I.
    Zhu, Motao
    Xiang, Henry
    Smith, Gary A.
    JOURNAL OF MEDICAL TOXICOLOGY, 2025, : 241 - 252
  • [9] Mediators of racial and ethnic inequities in clinical trial participation among patients with cancer, 2011-2023
    Guadamuz, Jenny S.
    Wang, Xiaoliang
    Altomare, Ivy
    Castillo, Wendy Camelo
    Sarkar, Somnath
    Mamtani, Ronac
    Calip, Gregory S.
    JNCI CANCER SPECTRUM, 2024, 8 (05)
  • [10] Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
    Michaeli, Daniel Tobias
    Michaeli, Thomas
    Albers, Sebastian
    Boch, Tobias
    Michaeli, Julia Caroline
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2024, 25 (06): : 979 - 997
12345